EXEL

Exelixis, Inc.

Exelixis Inc is a part of the healthcare sector. As a biotechnology company, it develops small molecule therapies for the treatment of cancer.

Exelixis, Inc. (EXEL) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-16 B- (3.0) C (2.3) A- (3.9) A- (4.0) B- (3.0) B (3.2)
2026-11-09 B- (3.0) C (2.3) A- (3.9) A- (4.0) B- (3.0) B (3.2)
2026-11-03 B- (3.0) C (2.3) A- (3.9) A- (3.9) B- (3.0) B (3.2)
2026-11-02 B- (3.0) C (2.3) A- (3.9) B+ (3.7) B (3.3) B (3.2)
2026-11-01 B- (3.0) C (2.3) A- (3.9) B (3.5) B (3.3) B (3.2)
Page 1 of 2

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe